J.P. Morgan reiterates its OW rating on Human Genome Sciences, Inc. HGSI following the positive FDA panel that overwhelmingly recommended the approval of Benlysta for systemic lupus.
“As we had speculated, the drug's safety profile and the disease's unmet medical need ultimately won out in the end,” J.P. Morgan writes. “We review our real-time panel thoughts, published throughout the day, in the body of this note, but below we focus more on where we go from here and on our take heading into the Dec 9th PDUFA.”
Human Genome Sciences currently trades at $24.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in